Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Receivables: 2010-2025

Historic Change in Receivables for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2025 value amounting to -$1.3 million.

  • Anika Therapeutics' Change in Receivables rose 72.92% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 123.83%. This contributed to the annual value of -$3.4 million for FY2024, which is 357.93% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Change in Receivables is -$1.3 million, which was down 154.48% from $2.4 million recorded in Q2 2025.
  • Anika Therapeutics' Change in Receivables' 5-year high stood at $6.2 million during Q2 2023, with a 5-year trough of -$4.8 million in Q3 2024.
  • In the last 3 years, Anika Therapeutics' Change in Receivables had a median value of -$1.3 million in 2025 and averaged -$364,909.
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 285.53% in 2021, then plummeted by 959.27% in 2023.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Change in Receivables stood at -$2.1 million in 2021, then surged by 130.74% to $647,000 in 2022, then skyrocketed by 70.63% to $1.1 million in 2023, then skyrocketed by 196.38% to $3.3 million in 2024, then soared by 72.92% to -$1.3 million in 2025.
  • Its Change in Receivables was -$1.3 million in Q3 2025, compared to $2.4 million in Q2 2025 and -$3.0 million in Q1 2025.